Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077961
Status:
TERMINATED
Last Update Posted:
2015-03-26
First Post:
2004-02-13
Brief Title:
Rituximab Plus CAMPATH in Patients With RelapsedRefractory Low-Grade or Follicular CD20-positive B-cell NHL
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi